Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
Current reports
8-K
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
14 Mar 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Dec 23
8-K
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
27 Oct 23
8-K
Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026
3 Oct 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
8-K
Other Events
11 Aug 23
8-K
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
8-K
Departure of Directors or Certain Officers
26 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8
Registration of securities for employees
14 Mar 24
S-8
Registration of securities for employees
11 May 23
POS AM
Prospectus update (post-effective amendment)
14 Mar 23
POSASR
Automatic shelf registration (post-effective amendment)
14 Mar 23
S-8
Registration of securities for employees
17 Mar 22
S-3ASR
Automatic shelf registration
20 Dec 21
424B5
Prospectus supplement for primary offering
19 Nov 21
S-8
Registration of securities for employees
11 Mar 21
424B5
Prospectus supplement for primary offering
23 Sep 20
Proxies
PRE 14A
Preliminary proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
2 Jun 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
8 May 23
EFFECT
Notice of effectiveness
24 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20
UPLOAD
Letter from SEC
18 Sep 20
EFFECT
Notice of effectiveness
12 Jul 19
CORRESP
Correspondence with SEC
9 Jul 19
UPLOAD
Letter from SEC
9 Jul 19
CT ORDER
Confidential treatment order
21 Jun 18
EFFECT
Notice of effectiveness
21 Jun 18
CERT
Certification of approval for exchange listing
19 Jun 18
Ownership
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G
BARCLAYS PLC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
22 Jan 24
3
Mark C. Schiller
17 Jan 24
4
Marc Belsky
9 Jan 24